This company listing is no longer active
Forward Pharma (1FPB) Stock Overview
Forward Pharma A/S does not have significant operations. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
1FPB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Forward Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.76 |
| 52 Week High | US$5.45 |
| 52 Week Low | US$1.47 |
| Beta | 1.65 |
| 1 Month Change | 0% |
| 3 Month Change | 1.15% |
| 1 Year Change | -65.15% |
| 3 Year Change | -63.64% |
| 5 Year Change | -85.87% |
| Change since IPO | -98.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1FPB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | 2.6% |
| 1Y | -65.1% | 3.3% | 11.4% |
Return vs Industry: 1FPB underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 1FPB underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 1FPB volatility | |
|---|---|
| 1FPB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 13.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 1FPB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 1FPB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4 | Claus Bo Svendsen | www.forward-pharma.com |
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Forward Pharma A/S Fundamentals Summary
| 1FPB fundamental statistics | |
|---|---|
| Market cap | €14.06m |
| Earnings (TTM) | -€521.80k |
| Revenue (TTM) | n/a |
Is 1FPB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1FPB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$566.00k |
| Earnings | -US$566.00k |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.7% |
How did 1FPB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/02 14:35 |
| End of Day Share Price | 2023/01/04 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Forward Pharma A/S is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Butler | Citizens JMP Securities, LLC |
| Thomas Wei | Jefferies LLC |
| Jason Matthew Gerberry | Leerink Partners LLC |